Key facts
- NeuroFlow’s last known valuation is $307.0M.
- It has raised $122.3M across 5 recorded rounds; the latest was Early Stage VC ($25.5M) in Jul 2022.
- Notable investors include Alumni Ventures, US National Science Foundation, MedTech Innovator, GV, F-Prime Capital — 45 tracked in total.
- NeuroFlow has filed 5 Form Ds with the SEC since 2017, most recently Oct 2022 ($25.5M sold to 19 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 45 names
- ·Watchlist + deal alerts for NeuroFlow
Funding rounds
5 roundsAbout NeuroFlow
Developer of behavioral health integration technology designed to support coordinated care and informed decision-making in healthcare organizations. The company's platform provides cloud-based tools compliant with healthcare privacy regulations for population-level risk identification, remote patient monitoring, structured risk assessment, and care workflow coordination, enabling payors, health systems, and public sector health entities to better understand behavioral health needs and manage care more effectively.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Employees
- 200
- Website
- neuroflow.com/
- Ownership
- Privately Held (backing)
NeuroFlow doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NeuroFlow shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NeuroFlow in its N-PORT filings yet. We sweep new filings monthly.